

Munich, July 1, 2025

Siemens completes acquisition of Dotmatics

- **Acquisition successfully closed for enterprise value of \$5.1 billion**
- **Siemens expands AI-powered Siemens Xcelerator portfolio with end-to-end digital thread that connects data from research through to production in Life Sciences**
- **Combined capabilities expected to accelerate scientific innovation and drive long-term growth**
- **Acquisition is another milestone of Siemens' ONE Tech Company program expanding Siemens' offerings into the life sciences industry with stronger customer focus, faster innovations and higher profitable growth**

Siemens AG announced today that it has completed the acquisition of Dotmatics, a leading provider of Life Sciences R&D software headquartered in Boston and portfolio company of global software investor Insight Partners, for an enterprise value of \$5.1 billion. With the transaction now completed, Dotmatics will form part of Siemens' Digital Industries Software business, marking a significant expansion of Siemens' industry-leading Product Lifecycle Management (PLM) portfolio into the rapidly growing and complementary Life Sciences market.

The acquisition of Dotmatics strengthens Siemens' position as a global leader in AI-powered PLM software and enables Siemens to scale its technologies into Life Sciences to fully address growth opportunities in this market. Dotmatics' Scientific Intelligence Platform, Luma, and its industry-leading scientific applications enable AI-powered multi-modal drug development, seamless collaboration, and contextualized data creating a connected digital thread across the research-to-production value chain.

“With Dotmatics, we’re building a new era of innovation in Life Sciences. From research through to production – we’re creating a unique, end-to-end digital thread: We combine Dotmatics’ scientific intelligence with our industrial AI technologies and digital twins,” said Roland Busch, President and CEO of Siemens AG. “This will allow us to help our customers accelerate breakthroughs, reduce development cycles, and bring life-saving pharmaceuticals faster and more affordably to the market.”

This transaction expands Siemens’ total addressable market for industrial software by \$11 billion and aligns with ‘ONE Tech Company’, the company’s strategic growth program, aimed at accelerating innovation and creating value across industries. Dotmatics is expected to generate more than \$300 million in revenue in fiscal year 2025 with an adjusted EBITDA margin above 40 percent, further enhancing Siemens’ growth profile. Dotmatics’ revenue growth and high profitability will be immediately accretive to Siemens’ growth, EBITDA margins and free cash flow, prior to any synergies and special items. Siemens expects substantial revenue synergies: Medium-term revenue synergies expected of around \$100 million per year accelerating to over \$500 million per year in the long-term.

This press release is available at: <https://sie.ag/5CwL67>

Contacts for journalists

Katharina Hilpert

Phone: +49 173 893-4962; email: katharina.hilpert@siemens.com

Simon Friedle

Phone: +49 1525 215-9076; email: simon.friedle@siemens.com

Noah Cole

Phone: +1 503 784-7958; email noah.cole@siemens.com

Follow us at: www.x.com/siemens_press

Siemens AG (Berlin and Munich) is a leading technology company focused on industry, infrastructure, mobility, and healthcare. The company's purpose is to create technology to transform the everyday, for everyone. By combining the real and the digital worlds, Siemens empowers customers to accelerate their digital and sustainability transformations, making factories more efficient, cities more livable, and transportation more sustainable. A leader in industrial AI, Siemens leverages its deep domain know-how to apply AI – including generative AI – to real-world applications, making AI accessible and impactful for customers across diverse industries. Siemens also owns a majority stake in the publicly listed company Siemens Healthineers, a leading global medical technology provider pioneering breakthroughs in healthcare. For everyone. Everywhere. Sustainably.

In fiscal 2024, which ended on September 30, 2024, the Siemens Group generated revenue of €75.9 billion and net income of €9.0 billion. As of September 30, 2024, the company employed around 312,000 people worldwide on the basis of continuing operations. Further information is available on the Internet at www.siemens.com.

Notes and forward-looking statements

This document contains statements related to our future business and financial performance and future events or developments involving Siemens that may constitute forward-looking statements. These statements may be identified by words such as “expect,” “look forward to,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “estimate,” “will,” “project” or words of similar meaning. We may also make forward-looking statements in other reports, in prospectuses, in presentations, in material delivered to shareholders and in press releases. In addition, our representatives may from time to time make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Siemens' management, of which many are beyond Siemens' control. These are subject to a number of risks, uncertainties and factors, including, but not limited to those described in disclosures, in particular in the chapter Report on expected developments and associated material opportunities and risks in the Combined Management Report of the Siemens Report (www.siemens.com/siemensreport), and in the Interim Group Management Report of the Half-year Financial Report (provided that it is already available for the current reporting year), which should be read in conjunction with the Combined Management Report. Should one or more of these risks or uncertainties materialize, should decrees, decisions, assessments or requirements of regulatory or governmental authorities deviate from our expectations, should events of force majeure, such as pandemics, unrest or acts of war, occur or should underlying expectations including future events occur at a later date or not at all or assumptions prove incorrect, actual results, performance or achievements of Siemens may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statement. Siemens neither intends, nor assumes any obligation, to update or revise these forward-looking statements in light of developments which differ from those anticipated.

This document includes – in the applicable financial reporting framework not clearly defined – supplemental financial measures that are or may be alternative performance measures (non-GAAP-measures). These supplemental financial measures should not be viewed in isolation or as alternatives to measures of Siemens' net assets and financial positions or results of operations as presented in accordance with the applicable financial reporting framework in its Consolidated Financial Statements. Other companies that report or describe similarly titled alternative performance measures may calculate them differently.

Due to rounding, numbers presented throughout this and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.